ACRIN

ACRIN ACRIN was a United States–based cooperative group focused on clinical research in diagnostic imaging, particularly oncologic imaging, established in the late 20th century and later integrated into a larger national network. It conducted multicenter trials involving imaging modalities and biomarkers to improve diagnosis, staging, and treatment assessment in cancer and other diseases. The organization worked with academic centers, professional societies, and federal agencies to design, conduct, and analyze imaging-focused clinical research across North America.

History

ACRIN was formed in 1999 under the auspices of the American College of Radiology to consolidate expertise in radiologic clinical trials and to respond to growing needs for standardized imaging protocols in oncology and cardiology. Its early initiatives built on prior cooperative efforts such as the Eastern Cooperative Oncology Group imaging initiatives and collaborations with the National Cancer Institute that addressed variability in imaging interpretation. During the 2000s ACRIN expanded trial portfolios to include multicenter studies involving positron emission tomography, magnetic resonance imaging, and computed tomography, aligning efforts with federal programs like the National Institutes of Health and networks such as the Cancer Imaging Program. In 2014 ACRIN merged into a larger cooperative structure under the Alliance for Clinical Trials in Oncology reconfigurations and related consortium efforts to streamline national oncology research infrastructure and to align with the Precision Medicine Initiative directions.

Organization and governance

ACRIN operated as a cooperative group with a governance model that included an Executive Committee, protocol committees, data management teams, and institutional review oversight drawn from participating academic centers. Leadership roles were commonly filled by faculty from institutions such as Johns Hopkins University, Massachusetts General Hospital, Mayo Clinic, and Memorial Sloan Kettering Cancer Center. Institutional participation entailed affiliations with universities and hospitals including University of Pennsylvania, Stanford University School of Medicine, Duke University Hospital, and University of California, San Francisco contributing investigators, radiologists, and biostatisticians. Oversight and funding mechanisms engaged federal stakeholders such as the National Cancer Institute and collaborated with professional organizations including the Radiological Society of North America and the Society of Nuclear Medicine and Molecular Imaging to maintain standards for imaging acquisition, review, and credentialing.

Research programs and clinical trials

ACRIN’s research programs spanned diagnostic accuracy, prognostic imaging biomarkers, and response assessment across malignancies including breast, lung, colorectal, prostate, and brain cancers. Landmark trials evaluated modalities such as fluorodeoxyglucose positron emission tomography (FDG-PET) for staging in non-small cell lung cancer and breast cancer imaging trials that compared mammography with adjunctive modalities, involving centers like Beth Israel Deaconess Medical Center and Cleveland Clinic. Trials incorporated quantitative imaging biomarkers tied to initiatives like the Quantitative Imaging Biomarkers Alliance and aligned with standards from the Food and Drug Administration for imaging endpoints. Protocols addressed technical aspects—image acquisition, central review, and quality control—with biostatistics support from groups linked to Fred Hutchinson Cancer Research Center and Memorial Sloan Kettering Cancer Center. ACRIN studies also intersected with therapeutic trials from cooperative groups such as the Eastern Cooperative Oncology Group and Alliance for Clinical Trials in Oncology to integrate imaging endpoints into treatment studies.

Collaborations and partnerships

ACRIN maintained extensive collaborations with federal agencies, academic institutions, industry partners, and professional societies. Key federal collaborations included projects with the National Institutes of Health, National Cancer Institute, and participation in multicenter programs coordinated with the Clinical Trials Cooperative Group Program. Academic partnerships spanned universities such as Yale School of Medicine, University of Michigan, University of Chicago, and Columbia University Irving Medical Center. Industry partnerships involved imaging equipment manufacturers and pharmaceutical companies for tracer development and device optimization, engaging entities linked to major conferences like American Society of Clinical Oncology and European Society for Medical Oncology for dissemination. Professional society liaisons included the American Society of Clinical Oncology, the Radiological Society of North America, and the American Association of Physicists in Medicine to harmonize guidelines and credentialing.

Impact and legacy

ACRIN’s legacy includes standardized imaging protocols, validated quantitative imaging biomarkers, and methodological frameworks that improved reproducibility in multicenter imaging trials. Its work influenced guidance from regulatory bodies such as the Food and Drug Administration on imaging endpoints and informed clinical practice guidelines from organisations like the American College of Radiology and the American Society of Clinical Oncology. Trial results shaped staging and response assessment in malignancies evaluated at centers including University of Texas MD Anderson Cancer Center and Stanford University Hospital. Data archives and standards developed by ACRIN contributed to subsequent initiatives in radiomics, imaging biomarker qualification, and integrated diagnostics in precision oncology efforts inspired by programs like the All of Us Research Program. The consolidation of ACRIN into broader cooperative structures preserved its datasets, methodological contributions, and the expertise of investigators now active in national and international imaging research networks.

Category:Medical research organizations